drugset / Trial / NCT05450601
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
A multicenter, randomized, double-blind, phase III study to evaluate the efficacy and safety of HCP2102 in patients with essential hypertension
Timeline
- Start
- 2022-09-01
- Primary completion
- 2023-12-11
- Completion
- 2023-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HCP2102 | Unknown | — | Oral |
| Comparator | RLD2106 | Unknown | — | Oral |